Bio-Path (NASDAQ:BPTH) Coverage Initiated at

Equities researchers at began coverage on shares of Bio-Path (NASDAQ:BPTHGet Rating) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the stock.

Separately, Roth Capital reissued a “buy” rating on shares of Bio-Path in a research report on Friday, March 17th.

Bio-Path Price Performance

NASDAQ:BPTH opened at $1.71 on Wednesday. The firm has a 50-day moving average of $1.48 and a 200-day moving average of $1.62. The company has a market cap of $13.61 million, a PE ratio of -0.81 and a beta of 1.30. Bio-Path has a one year low of $1.18 and a one year high of $4.48.

Bio-Path (NASDAQ:BPTHGet Rating) last posted its earnings results on Friday, March 31st. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.08). On average, equities research analysts expect that Bio-Path will post -1.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bio-Path

A number of institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new stake in Bio-Path in the 1st quarter worth about $38,000. Citadel Advisors LLC purchased a new position in Bio-Path in the third quarter valued at about $35,000. Renaissance Technologies LLC purchased a new position in Bio-Path in the second quarter valued at about $70,000. Finally, Mount Yale Investment Advisors LLC purchased a new position in Bio-Path in the third quarter valued at about $81,000. 6.42% of the stock is owned by institutional investors.

Bio-Path Company Profile

(Get Rating)

Bio-Path Holdings, Inc is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

Further Reading

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with's FREE daily email newsletter.